Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

August 31, 2013

Conditions
HIVHuman Papillomavirus
Interventions
BIOLOGICAL

Gardasil

Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.

BIOLOGICAL

Cervarix

Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.

Trial Locations (1)

8200

Department of Infectious Diseases, Aarhus University Hospital, Aarhus N

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

lead

University of Aarhus

OTHER

NCT01386164 - Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults | Biotech Hunter | Biotech Hunter